Clinical study in new protocol of anti-VEGF agents for macular edema with retinal vein occlusion and in relation between the protocol and cytokines

Clinical study in new protocol of anti-VEGF agents for macular edema with retinal vein occlusion and in relation between the protocol and cytokines - Relationship between new protocol of anti-VEGF agents and cytokines for RVO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030311

Enrollment

100

Registered

2017-12-09

Start date

2017-06-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Vein Occlusion

Interventions

injection of anti-VEGF agents 0.05 ml (first time and at the inactivate interval)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)visual acuity <0.9 2)central macular thickness > 300

Exclusion criteria

Exclusion criteria: 1)patients who were performed operation 2)patients with active uveitis 3)patients with rubeosis 4)patients with uncontrolled glaucoma 5)patients with severe diabetic retinopathy

Design outcomes

Primary

Measure	Time frame
visual acuity and central macular thickness every month	—

Countries

Japan

Contacts

Public ContactHidetaka Noma

Hachioji Medical Center, Tokyo Medical University Department of Ophthalmology

noma-hide@umin.ac.jp042-665-5611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026